# Detection of Plasma DNA Methylation in Peripheral Blood From Patients With Resectable Liver Cancer

> **NCT04856046** · — · ACTIVE_NOT_RECRUITING · sponsor: **Mayo Clinic** · enrollment: 36 (actual)

## Conditions studied

- Resectable Hepatocellular Carcinoma

## Interventions

- **PROCEDURE:** Biospecimen Collection
- **OTHER:** Electronic Health Record Review

## Key facts

- **NCT ID:** NCT04856046
- **Lead sponsor:** Mayo Clinic
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-11-06
- **Primary completion:** 2029-12-04
- **Final completion:** 2029-12-04
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2026-04-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04856046

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04856046, "Detection of Plasma DNA Methylation in Peripheral Blood From Patients With Resectable Liver Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04856046. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*